TY - JOUR AU - Kunjithapatham, Rani AU - Geschwind, Jean-Francois H. AU - Rao, Pramod P. AU - Boronina, Tatiana N. AU - Cole, Robert N. AU - Ganapathy-Kanniappan, Shanmugasundaram PY - 2013 DA - 2013/07/17 TI - Systemic administration of 3-bromopyruvate reveals its interaction with serum proteins in a rat model JO - BMC Research Notes SP - 277 VL - 6 IS - 1 AB - 3-bromopyruvate (3-BrPA) is a glycolytic inhibitor that affects cancer cells by targeting energy metabolism. Preclinical reports have established that a 1.75 mM dose of 3-BrPA is effective and sufficient to inhibit tumor growth when administered under a loco-regional approach (intraarterial and intratumoral). This loco-regional therapeutic dose was found to be nontoxic when given systemically as well. Yet, the mechanism underlying this lack of toxicity of 1.75 mM 3-BrPA during systemic delivery is unknown. Here, we investigated the mechanism associated with the lack of organ toxicity when 1.75 mM 3-BrPA was administered systemically using radiolabeled (14C)-3-BrPA in Sprague–Dawley rats. SN - 1756-0500 UR - https://doi.org/10.1186/1756-0500-6-277 DO - 10.1186/1756-0500-6-277 ID - Kunjithapatham2013 ER -